ELOXX PHARMACEUTICALS INC
ELOXNASDAQTrading Snapshot
- Day Range
- $12.55 – $13.78
- 52-Week Range
- $0.00 – $23.40
- Volume (shares)
- 1,202.525
- Avg Volume (shares)
- —
- Shares Outstanding
- 4.0M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 329.7x
- EPS (TTM)
- $-7.06
- Dividend Yield
- —
- Dilution (1yr)
- +38.9%
ELOXX PHARMACEUTICALS INC
ELOX
StockOtter · stockotter.spaceAbout ELOXX PHARMACEUTICALS INC
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD
FDA clearance of the IND enables Eloxx to open U.S. clinical sites for EXPRESS, its global Phase 2 study of exaluren in nonsense-mutation ADPKD EXPRESS will randomize approximately 60 patients 1:1 to exaluren or placebo
Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D.
EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to ex aluren or placebo, with annualized htTKV growth as the primary endpoint Substantial, durable htTKV effect could suppo
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
Mr. Germano brings more than 35 years of biopharmaceutical leadership experience, including as Group President of Pfizer's Global Innovative Pharmaceutical business Extensive public company board experience, including cu
This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Head to Head Comparison: Eloxx Pharmaceuticals (NASDAQ:ELOX) & LENZ Therapeutics (NASDAQ:LENZ)
LENZ Therapeutics (NASDAQ: LENZ - Get Free Report) and Eloxx Pharmaceuticals (NASDAQ: ELOX - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companie
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
First two patients dosed in the EXACT study Topline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final readout expected by the end of 2027 ARLINGTON, Mass., Sept. 11, 2026 /PRN